Hydroxychloroquine: Lupus Rheumatoid Arthritis and Malaria
Hydroxychloroquine (HCQ) is an antimalarial drug that has been in medical use since the 1950s and has established itself as a cornerstone of treatment for systemic lupus erythematosus (SLE) and rheumatoid arthritis. It is closely related to chloroquine but has a more favorable safety profile due to less tissue accumulation and lower toxicity. The drug belongs to the class of disease-modifying antirheumatic drugs (DMARDs) and immunomodulators.
Hydroxychloroquine is unique among DMARDs in that it has demonstrated not only anti-inflammatory effects but also cardiovascular protective effects in lupus patients, including reduced risk of thrombosis, damage accrual, and overall mortality. Its relatively favorable safety profile compared to other DMARDs, combined with decades of clinical experience, makes it the standard background medication for virtually all patients with systemic lupus who are able to tolerate it.
Mechanism of Action
Hydroxychloroquine is a weak base that accumulates in acidic intracellular compartments such as lysosomes, endosomes, and autophagosomes, raising their pH. This lysosomal alkalinization disrupts multiple processes critical for innate and adaptive immune activation. In lysosomes, antigen processing requires an acidic environment; impaired antigen presentation reduces T cell activation. In plasmacytoid dendritic cells, HCQ blocks Toll-like receptor 7 and 9 signaling by preventing endosomal acidification, thereby reducing type I interferon production, which is a key driver of lupus activity. HCQ also inhibits the NLRP3 inflammasome, reduces pro-inflammatory cytokine release (IL-1, IL-6, TNF-alpha), and interferes with arachidonic acid metabolism. These combined effects result in broad immunomodulation without the immunosuppression characteristic of corticosteroids or cytotoxic agents.
Indications
Hydroxychloroquine is approved for the treatment of systemic lupus erythematosus in adults and children, for cutaneous lupus erythematosus (discoid lupus), for rheumatoid arthritis, and for malaria prophylaxis and treatment in regions with chloroquine-sensitive strains. In rheumatology, HCQ is recommended as background therapy in virtually all SLE patients unless specifically contraindicated, due to its well-documented benefits in reducing flare frequency, preventing organ damage accumulation, reducing thrombosis risk in antiphospholipid syndrome, and reducing overall mortality. In rheumatoid arthritis, it is used in combination with other DMARDs, particularly in the triple therapy regimen with methotrexate and sulfasalazine.
Dosage and Administration
The recommended dose for immunomodulatory use is a maximum of 5 mg per kg of actual body weight per day, based on evidence that doses above this threshold significantly increase the risk of retinal toxicity. For a person weighing 60 kg, this means a maximum of 300 mg daily; for 70 kg, 350 mg daily. Most patients receive 200 to 400 mg daily in one or two divided doses taken with food to reduce gastrointestinal side effects. The therapeutic effect in rheumatic conditions typically requires 4 to 12 weeks to become apparent; the full effect may take several months. In malaria chemoprophylaxis, HCQ is taken weekly starting one to two weeks before entering an endemic area, continued throughout the stay, and for four weeks after departure.
Side Effects
Gastrointestinal complaints including nausea, vomiting, diarrhea, and abdominal discomfort are the most common side effects and can usually be managed by taking the drug with food or splitting the daily dose. Skin reactions including rash, pruritus, and photosensitivity occur in a minority of patients. Headache and dizziness are reported occasionally. The most clinically significant adverse effect is retinal toxicity (hydroxychloroquine retinopathy), which is a dose-dependent, cumulative effect that can lead to irreversible visual loss if not detected early. The risk is low during the first five years at recommended doses (below 1 percent) but increases substantially with longer duration and higher cumulative doses. Annual ophthalmic screening using optical coherence tomography (OCT) and visual field testing is mandatory after the first five years of use, or from year one in patients with additional risk factors such as renal impairment. Cardiac conduction effects (QT prolongation) are possible, particularly at higher doses or in combination with other QT-prolonging drugs.
Interactions
Hydroxychloroquine can prolong the QT interval; combined use with other QT-prolonging agents (antidepressants, antipsychotics, azithromycin, fluoroquinolones) increases the risk of cardiac arrhythmias. Antacids containing aluminum and magnesium may reduce HCQ absorption; a gap of several hours between ingestion is recommended. HCQ may increase plasma levels of digoxin and metoprolol, requiring monitoring. In patients receiving insulin or oral antidiabetic agents, HCQ can enhance hypoglycaemic effects through its modest blood glucose-lowering properties, requiring dose adjustments. Tamoxifen combined with HCQ significantly increases the risk of retinopathy and this combination should be avoided or subject to intensified ophthalmological monitoring.
Special Notes
Hydroxychloroquine is considered one of the safer DMARDs for use in pregnancy and is recommended to be continued throughout pregnancy in women with lupus, as discontinuation increases the risk of flares with potentially serious consequences for mother and fetus. Neonatal safety data are extensive and reassuring. The drug passes into breast milk in small amounts; guidelines generally consider breastfeeding compatible with HCQ use under medical supervision. G6PD deficiency is a relative contraindication, particularly at higher doses, as HCQ can precipitate haemolytic anaemia in affected patients. Before initiating therapy, a baseline ophthalmological examination and assessment of renal function are recommended to stratify retinopathy risk.
Related Active Ingredients
Frequently Asked Questions
Why are annual eye examinations required with hydroxychloroquine?
Hydroxychloroquine accumulates in retinal pigment epithelium cells, where over years it can cause irreversible photoreceptor damage. Retinopathy is dose-dependent and cumulative. Once vision loss from HCQ retinopathy develops, it is irreversible and may even progress after stopping the drug. Annual screening with OCT and visual field testing after the first five years of treatment allows detection at an early, asymptomatic stage when stopping the drug can prevent further damage.
Is hydroxychloroquine safe in pregnancy?
Yes. Hydroxychloroquine is considered one of the safest medications for use in pregnancy among DMARDs. Decades of data from lupus pregnancies show no increase in teratogenicity. Importantly, stopping HCQ during pregnancy significantly increases the risk of lupus flares, which carry their own risks for mother and fetus. Current guidelines actively recommend continuing HCQ throughout pregnancy and breastfeeding in women with SLE.
Why is the dose limited to 5 mg per kg per day?
This weight-based dosing limit was established through epidemiological studies showing a clear dose-response relationship between daily HCQ dose and the risk of retinal toxicity. Earlier fixed dosing recommendations of 400 mg daily without weight adjustment resulted in relative overdosing in lighter patients. Keeping the dose at or below 5 mg per kg per day substantially reduces the cumulative retinal damage risk without compromising the therapeutic benefit in most patients.
Sources
- Marmor MF et al: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2016 (updated 2020)
- EULAR Recommendations for the Management of Systemic Lupus Erythematosus 2023
- Fanouriakis A et al: 2019 Update of EULAR recommendations for SLE. Ann Rheum Dis 2020